Pulmonary drug developer Liquidia posts operating profit in in first full quarter of YUTREPIA sales

Liquidia

03/11/2025 11:43

Corrects total revenue to $54.34 mln, from $51.7 mln, and removes comparison with estimates in Overview and Key Details sections

Overview

Liquidia posts Q3 total revenue of $54.34 mln

Company achieves operating profitability in first full quarter of YUTREPIA sales

Posts net loss; adjusted loss/share beats consensus

Outlook

Liquidia plans to advance L606 into pivotal trials

Company aims for sustained growth and profitability

Liquidia sees YUTREPIA as a potential preferred treatment

Result Drivers

YUTREPIA LAUNCH - Strong sales of YUTREPIA, with $51.7 mln in net product sales as launch momentum continues

PRESCRIPTION GROWTH - Over 2,000 unique prescriptions and 1,500 patient starts contributed to sales momentum, as of Oct 30

COST MANAGEMENT - Positive operating income and adjusted EBITDA reflect effective cost management alongside revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 TOTAL REVENUE
$54.34 mln
Q3 EPS
Beat
-$0.04
-$0.40 (9 Analysts)
Q3 NET INCOME
-$3.53 mln
Q3 Operating Income
$1.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Liquidia Corp is $37.00, about 34.2% above its October 31 closing price of $24.36

Press Release: ID:nGNX2FLzbw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)